278 related articles for article (PubMed ID: 28297630)
1. Genomics of Multiple Myeloma.
Robiou du Pont S; Cleynen A; Fontan C; Attal M; Munshi N; Corre J; Avet-Loiseau H
J Clin Oncol; 2017 Mar; 35(9):963-967. PubMed ID: 28297630
[TBL] [Abstract][Full Text] [Related]
2. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
[TBL] [Abstract][Full Text] [Related]
4. Multiple Myeloma Genomics: A Systematic Review.
Weaver CJ; Tariman JD
Semin Oncol Nurs; 2017 Aug; 33(3):237-253. PubMed ID: 28729121
[TBL] [Abstract][Full Text] [Related]
5. Genomic Aberrations in Multiple Myeloma.
Manier S; Salem K; Glavey SV; Roccaro AM; Ghobrial IM
Cancer Treat Res; 2016; 169():23-34. PubMed ID: 27696256
[TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Hervé AL; Florence M; Philippe M; Michel A; Thierry F; Kenneth A; Jean-Luc H; Nikhil M; Stéphane M
J Clin Oncol; 2011 May; 29(14):1893-7. PubMed ID: 21482986
[TBL] [Abstract][Full Text] [Related]
7. Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M; Bergsagel PL
Int J Lab Hematol; 2015 May; 37 Suppl 1():108-14. PubMed ID: 25976968
[TBL] [Abstract][Full Text] [Related]
8. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
9. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
[TBL] [Abstract][Full Text] [Related]
10. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.
Wuilleme S; Robillard N; Lodé L; Magrangeas F; Beris H; Harousseau JL; Proffitt J; Minvielle S; Avet-Loiseau H;
Leukemia; 2005 Feb; 19(2):275-8. PubMed ID: 15538401
[TBL] [Abstract][Full Text] [Related]
11. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract][Full Text] [Related]
12. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G; Cibulskis K; McKenna A; Chapman MA; Straussman R; Levy J; Perkins LM; Keats JJ; Schumacher SE; Rosenberg M; ; Getz G; Golub TR
Cancer Cell; 2014 Jan; 25(1):91-101. PubMed ID: 24434212
[TBL] [Abstract][Full Text] [Related]
13. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM
J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065
[TBL] [Abstract][Full Text] [Related]
15. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
16. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.
Perrot A; Corre J; Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2018 May; 38():675-680. PubMed ID: 30231368
[TBL] [Abstract][Full Text] [Related]
17. [The origin and formation of chromosomal translocations in multiple myeloma].
Nemec P; Kuglík P; Hájek R
Klin Onkol; 2008; 21(2):53-8. PubMed ID: 19102212
[TBL] [Abstract][Full Text] [Related]
18. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.
Kazandjian D; Hill E; Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Korde N; Mailankody S; Dew A; Papaemmanuil E; Maric I; Kwok M; Landgren O
Blood Cancer J; 2019 Feb; 9(2):15. PubMed ID: 30718460
[TBL] [Abstract][Full Text] [Related]
19. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
Walker BA; Wardell CP; Melchor L; Hulkki S; Potter NE; Johnson DC; Fenwick K; Kozarewa I; Gonzalez D; Lord CJ; Ashworth A; Davies FE; Morgan GJ
Blood; 2012 Aug; 120(5):1077-86. PubMed ID: 22573403
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic abnormalities in high-risk multiple myeloma].
Ishida T
Nihon Rinsho; 2015 Jan; 73(1):28-32. PubMed ID: 25626299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
